Literature DB >> 22684105

Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.

Roberto Bellucci1, Hong-Nam Nguyen, Allison Martin, Stefan Heinrichs, Anna C Schinzel, William C Hahn, Jerome Ritz.   

Abstract

Natural killer (NK) cells are primary effectors of innate immunity directed against transformed tumor cells. In response, tumor cells have developed mechanisms to evade NK cell-mediated lysis through molecular mechanisms that are not well understood. In the present study, we used a lentiviral shRNA library targeting more than 1,000 human genes to identify 83 genes that promote target cell resistance to human NK cell-mediated killing. Many of the genes identified in this genetic screen belong to common signaling pathways; however, none of them have previously been known to modulate susceptibility of human tumor cells to immunologic destruction. Gene silencing of two members of the JAK family (JAK1 and JAK2) increased the susceptibility of a variety of tumor cell types to NK-mediated lysis and induced increased secretion of IFN-γ by NK cells. Treatment of tumor cells with JAK inhibitors also increased susceptibility to NK cell activity. These findings may have important clinical implications and suggest that small molecule inhibitors of tyrosine kinases being developed as therapeutic antitumor agents may also have significant immunologic effects in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684105      PMCID: PMC3386806          DOI: 10.1172/JCI58457

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

Review 1.  Mammalian MAP kinase signalling cascades.

Authors:  L Chang; M Karin
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

2.  Human NK-cell receptors.

Authors:  L Moretta; R Biassoni; C Bottino; M C Mingari; A Moretta
Journal:  Immunol Today       Date:  2000-09

3.  Dasatinib suppresses in vitro natural killer cell cytotoxicity.

Authors:  Stephen J Blake; A Bruce Lyons; Cara K Fraser; John D Hayball; Timothy P Hughes
Journal:  Blood       Date:  2008-04-15       Impact factor: 22.113

Review 4.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

5.  Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells.

Authors:  K Jiang; B Zhong; D L Gilvary; B C Corliss; E Hong-Geller; S Wei; J Y Djeu
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

6.  Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway.

Authors:  S Wei; D L Gilvary; B C Corliss; S Sebti; J Sun; D B Straus; P J Leibson; J A Trapani; A D Hamilton; M J Weber; J Y Djeu
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

Review 7.  The TRAIL apoptotic pathway in cancer onset, progression and therapy.

Authors:  Ricky W Johnstone; Ailsa J Frew; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

8.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

9.  CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.

Authors:  Ron Firestein; Adam J Bass; So Young Kim; Ian F Dunn; Serena J Silver; Isil Guney; Ellen Freed; Azra H Ligon; Natalie Vena; Shuji Ogino; Milan G Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S Boehm; Supriya Jain; Emeric Bojarski; Craig Mermel; Jordi Barretina; Jennifer A Chan; Jose Baselga; Josep Tabernero; David E Root; Charles S Fuchs; Massimo Loda; Ramesh A Shivdasani; Matthew Meyerson; William C Hahn
Journal:  Nature       Date:  2008-09-14       Impact factor: 49.962

Review 10.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

View more
  13 in total

1.  Get a grip on immune cells by inhibiting JAKs.

Authors:  Kathrin Schönberg; Janna Rudolph; Sowmya Parampalli Yajnanarayana; Dominik Wolf
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss.

Authors:  B Gao; C Moore; F Porcheray; C Rong; C Abidoglu; J DeVito; R Paine; T C Girouard; S L Saidman; D Schoenfeld; B Levin; W Wong; N Elias; C Schuetz; I Rosales; Y Fu; E Zorn
Journal:  Am J Transplant       Date:  2014-06-16       Impact factor: 8.086

3.  Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.

Authors:  Davide Bommarito; Allison Martin; Edouard Forcade; Maria-Dorothea Nastke; Jerome Ritz; Roberto Bellucci
Journal:  Cancer Immunol Immunother       Date:  2016-02-16       Impact factor: 6.968

Review 4.  JAKs and STATs in immunity, immunodeficiency, and cancer.

Authors:  John J O'Shea; Steven M Holland; Louis M Staudt
Journal:  N Engl J Med       Date:  2013-01-10       Impact factor: 91.245

5.  c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.

Authors:  Joseph C Murray; Dalal Aldeghaither; Shangzi Wang; Rochelle E Nasto; Sandra A Jablonski; Yong Tang; Louis M Weiner
Journal:  Cancer Immunol Res       Date:  2014-10-09       Impact factor: 11.151

6.  A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.

Authors:  Nisit Khandelwal; Marco Breinig; Tobias Speck; Tillmann Michels; Christiane Kreutzer; Antonio Sorrentino; Ashwini Kumar Sharma; Ludmila Umansky; Heinke Conrad; Isabel Poschke; Rienk Offringa; Rainer König; Helga Bernhard; Arthur Machlenkin; Michael Boutros; Philipp Beckhove
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

7.  Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.

Authors:  Roberto Bellucci; Allison Martin; Davide Bommarito; Kathy Wang; Steen H Hansen; Gordon J Freeman; Jerome Ritz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 8.  Present and Future of Allogeneic Natural Killer Cell Therapy.

Authors:  Okjae Lim; Mi Young Jung; Yu Kyeong Hwang; Eui-Cheol Shin
Journal:  Front Immunol       Date:  2015-06-03       Impact factor: 7.561

9.  CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Authors:  J Chu; Y Deng; D M Benson; S He; T Hughes; J Zhang; Y Peng; H Mao; L Yi; K Ghoshal; X He; S M Devine; X Zhang; M A Caligiuri; C C Hofmeister; J Yu
Journal:  Leukemia       Date:  2013-09-26       Impact factor: 11.528

10.  Mapping the effects of drugs on the immune system.

Authors:  Brian A Kidd; Aleksandra Wroblewska; Mary R Boland; Judith Agudo; Miriam Merad; Nicholas P Tatonetti; Brian D Brown; Joel T Dudley
Journal:  Nat Biotechnol       Date:  2015-11-30       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.